Imiphumela Emangalisayo Yokwelashwa Kwe-CAR-T Okuqondiswe Ku-CD7 Kwe-T-ALL Ne-T-LBL

Ukuhlolwa kwamuva nje kwezokwelapha kubonise intuthuko enkulu ekwelapheni i-T-cell acute lymphoblastic leukemia (T-ALL) ephinde yabuya noma engaphikisi kanye ne-T-cell lymphoblastic lymphoma (T-LBL) kusetshenziswa ukwelashwa kwe-CD7-targeted chimeric antigen receptor (CAR) T cell. Ucwaningo, olwenziwe yithimba elivela e-Hebei Yanda Lu Daopei Hospital kanye ne-Lu Daopei Institute of Hematology, luhilele iziguli ezingu-60 ezithole umthamo owodwa wamaseli e-T akhethwe ngokwemvelo e-anti-CD7 CAR (NS7CAR).

Imiphumela yokuhlolwa iyakhuthaza kakhulu. Ngosuku lwama-28, ama-94.4% eziguli athole ukuxolelwa okuphelele (CR) emnkantsheni wethambo. Ngaphezu kwalokho, phakathi kweziguli ezingama-32 ezinesifo esingaphandle kwe-medullary, ama-78.1% abonise impendulo enhle, kanti ama-56.3% athole ukuxolelwa okuphelele kanye nama-21.9% athole ukuxolelwa okungaphelele. Amazinga okusinda okuphelele kweminyaka emibili kanye nokusinda okungenalo ukuqhubekela phambili ayengu-63.5% kanye nama-53.7%, ngokulandelana.

Lokhu kwelashwa okusha kuyaphawuleka ngephrofayili yayo yokuphepha elawulekayo, lapho i-cytokine release syndrome yenzeka ku-91.7% weziguli (ikakhulukazi ibanga 1/2), kanye nobuthi be-neurotoxic obubonwe ku-5% wamacala. Ngaphezu kwalokho, ucwaningo luthole ukuthi iziguli ezaqhubeka nokufakelwa izitho zokufakelwa ngemva kokufinyelela i-CR zazinamazinga okusinda aphezulu kakhulu angenawo ama-progression uma kuqhathaniswa nalezo ezingazange ziphumelele.

Inkampani yethu ihlola futhi amandla okwelashwa kwamaseli e-CD7 CAR-T ngomkhiqizo wethu okhethekile, okuhloswe ngawo ukufaka isandla ekuthuthukisweni kokwelashwa komdlavuza wamaseli e-T.

Lokhu okutholakele kugcizelela amandla okwelashwa kwamaseli e-CAR-T aqondiswe ku-CD7 ukuze kunikezwe ithemba elisha ezigulini ezine-T-ALL kanye ne-T-LBL ezingaphili noma eziphinde zabuyela ebudaleni, okuphawula ingqophamlando ebalulekile empini eqhubekayo yokulwa nalezi zifo eziyinselele.